Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Ono/BMS Sign Patent License Deal for Tecentriq with Roche
Ono Pharmaceutical said on November 9 that the company and Bristol Myers Squibb have entered into a global patent license agreement with Roche over the swiss giant’s anti-PD-L1 antibody Tecentriq (atezolizumab). Under the deal, Ono and BMS will receive from…
To read the full story
Related Article
- Ono to Pay 28 Billion Yen to Settle Opdivo Feud with Honjo
November 15, 2021
- Ono, Honjo to Continue Settlement Discussions in Opdivo Royalty Feud
September 24, 2021
- Court Pitches Settlement in Opdivo Royalty Row, Response Due Sept. 22
September 13, 2021
- Ono Chief, Honjo Remain Divided over Opdivo Royalty in Direct Face-Off
September 3, 2021
- Honjo Ups Royalty Claim after Tecentriq Settlement: Opdivo Row
June 14, 2021
BUSINESS
- Takeda to Nominate CEO-Elect Kim to Board at June AGM
March 27, 2026
- Sephience Seen as Potential First-Line PKU Therapy: Professor
March 27, 2026
- Meiji Pharma, KM Biologics Begin PIII for 6-in-1 Vaccine
March 27, 2026
- J-TEC Files Dried Allogeneic Cultured Epidermis in Japan
March 27, 2026
- Pfizer Seeks Methotrexate Label Expansion for GVHD Prevention
March 27, 2026
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…